153 related articles for article (PubMed ID: 15543232)
1. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Nasr R; El-Sabban ME; Karam JA; Dbaibo G; Kfoury Y; Arnulf B; Lepelletier Y; Bex F; de Thé H; Hermine O; Bazarbachi A
Oncogene; 2005 Jan; 24(3):419-30. PubMed ID: 15543232
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells.
Darwiche N; Hatoum A; Dbaibo G; Kadara H; Nasr R; Abou-Lteif G; Bazzi R; Hermine O; de Thé H; Bazarbachi A
Leukemia; 2004 Mar; 18(3):607-15. PubMed ID: 14712289
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
[TBL] [Abstract][Full Text] [Related]
6. EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
Moarbess G; El-Hajj H; Kfoury Y; El-Sabban ME; Lepelletier Y; Hermine O; Deleuze-Masquéfa C; Bonnet PA; Bazarbachi A
Blood; 2008 Apr; 111(7):3770-7. PubMed ID: 18218850
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
8. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
Goel A; Dispenzieri A; Greipp PR; Witzig TE; Mesa RA; Russell SJ
Exp Hematol; 2005 Jul; 33(7):784-95. PubMed ID: 15963854
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
10. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Abou-Merhi R; Khoriaty R; Arnoult D; El Hajj H; Dbouk H; Munier S; El-Sabban ME; Hermine O; Gessain A; de Thé H; Mahieux R; Bazarbachi A
Leukemia; 2007 Aug; 21(8):1792-801. PubMed ID: 17568816
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
13. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB.
Nishioka C; Ikezoe T; Yang J; Komatsu N; Bandobashi K; Taniguchi A; Kuwayama Y; Togitani K; Koeffler HP; Taguchi H
Leuk Res; 2008 Feb; 32(2):287-96. PubMed ID: 17644177
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas.
Darwiche N; Sinjab A; Abou-Lteif G; Chedid MB; Hermine O; Dbaibo G; Bazarbachi A
Int J Cancer; 2011 Aug; 129(4):993-1004. PubMed ID: 21064094
[TBL] [Abstract][Full Text] [Related]
16. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Horie R; Watanabe T; Umezawa K
Drug News Perspect; 2006 May; 19(4):201-9. PubMed ID: 16823495
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
18. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Pei XY; Dai Y; Grant S
Leukemia; 2003 Oct; 17(10):2036-45. PubMed ID: 14513055
[TBL] [Abstract][Full Text] [Related]
20. Role of intracellular redox status in apoptosis induction of human T-cell leukemia virus type I-infected lymphocytes by 13-cis-retinoic acid.
Furuke K; Sasada T; Ueda-Taniguchi Y; Yamauchi A; Inamoto T; Yamaoka Y; Masutani H; Yodoi J
Cancer Res; 1997 Nov; 57(21):4916-23. PubMed ID: 9354458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]